Results 101 to 110 of about 53,515 (238)

Circumscribed Meningeal Melanocytic Neoplasms: CNS WHO Grade, Molecular Profile, and Clinical Outcomes

open access: yesBrain Pathology, EarlyView.
In this study including 31 circumscribed meningeal melanocytic neoplasms (melanocytoma, intermediate‐grade melanocytic tumor [IMT], and melanoma), overall survival (OS) differed significantly among the groups, with melanoma showing significantly worse OS than melanocytoma and IMT showing intermediate OS between melanocytoma and melanoma.
Yi Zhu   +12 more
wiley   +1 more source

Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma

open access: yesFrontiers in Neurology, 2018
In daily clinical practice, there is a growing number of patients receiving new biological agents used in the treatment of malignancies. Ipilimumab is a fully humanized monoclonal antibody approved for patients with melanoma.
Vera Montes   +4 more
doaj   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

open access: yesBritish Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu   +6 more
wiley   +1 more source

A Case of Erythema Multiforme Major Developed after Sequential Use of Two Immune Checkpoint Inhibitors, Nivolumab and Ipilimumab, for Advanced Melanoma: Possible Implication of Synergistic and/or Complementary Immunomodulatory Effects

open access: yesCase Reports in Dermatology, 2018
Immune checkpoint inhibitors, such as ipilimumab and nivolumab, reverse the imbalance of antitumor self-tolerance and enhance T-cell responses. Currently, ipilimumab and nivolumab have a reported therapeutic impact on unresectable or metastatic melanomas;
Akira Utsunomiya   +6 more
doaj   +1 more source

Real-world impact of education: treating patients with ipilimumab in a community practice setting

open access: yes, 2013
Blanca Ledezma,1 Annie Heng2 1Department of Hematology and Oncology, University of California, Los Angeles, Santa Monica, CA, USA; 2Angeles Clinic and Research Institute, Los Angeles, CA, USA Abstract: After decades without promising new treatments for ...
Heng A, Ledezma B
core  

Kaplan-Meier-Plots of patients treated with ipilimumab for metastatic melanoma according to different parameters.

open access: yes, 2018
Overall survival of patients treated with ipilimumab grouped by (A) BMI and (B) LDH levels. Progression-free survival rates of patients treated with ipilimumab, grouped by BMI (C).
Rainer Huegel (5807369)   +16 more
core   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia   +6 more
wiley   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes   +7 more
wiley   +1 more source

Refining the treatment of immune checkpoint inhibitor–associated myocarditis: Challenges, innovations and rechallenge considerations

open access: yesBritish Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy